Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS

Stock Information for Aquestive Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aquestive Therapeutics Inc.

Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
Aquestive Therapeutics to Present Crossover Study Data for Libervant(TM) (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
Aquestive Therapeutics Announces Pivotal Study for Anaphylm(TM) (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.